Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
Company planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration and begin a Phase 1
Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue
Protein degrader intellectual property portfolio now includes 16 issued patents across six unique
Gainers
Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering.